Skip to main content

Advertisement

Table 3 Time trends in prevalence of medical comorbidity (in %) from 1993 to 2005 in patients undergoing primary THA

From: Increasing obesity and comorbidity in patients undergoing primary total hip arthroplasty in the U.S.: A 13-year study of time trends

  1993-1995 1996-1998 1999-2001 2002-2005 P-value
Deyo-Charlson comorbidities
 Myocardial Infarction 4.0 4.2 4.1 4.7 0.76
 Congestive Heart Failure 2.5 2.8 3.5 4.1 0.05
 Peripheral Vascular Disease 4.7 3.8 4.2 5.6 0.07
 Cerebrovascular disease 5.5 5.2 6.3 7.9 0.006
 Dementia 0 0 0.3 0.4 0.02
 COPD 9.7 8.8 10.2 9.7 0.66
 Peptic ulcer disease 5.5 6.3 6.2 6.3 0.81
 Mild liver disease 1.4 0.6 1.1 1.2 0.20
 Diabetes 4.8 5.0 5.9 8.0 <0.001
 Diabetes with end organ damage 0.9 0.7 1.8 2.0 0.005
 Hemiplegia 0.3 0.2 0.2 0.5 0.48
 Moderate/severe renal disease 2.6 3.2 5.4 5.9 <0.001
 Moderate/severe liver disease 0.5 0.3 0.2 0.3 0.58
 Metastatic solid tumor 3.3 2.3 3.6 2.7 0.12
 AIDS 0 0.1 0 0 0.32
 Rheumatologic disease 6.1 5.2 5.4 5.2 0.67
 Other cancer 11.2 10.9 13.5 13.9 0.02
Mean Deyo-Charlson score (SD) 0.9 (1.8) 0.9 (1.7) 1.1 (2.0) 1.1 (2.0) <0.001
  1. COPD, Chronic Obstructive Pulmonary Disease; AIDS, Acquired Immune Deficiency Disease; SD, standard deviation.
  2. Significant p-values are in bold, calculated with chi-squared test.